AAM
NTLA icon

Advisors Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Advisors Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,992
Closed -$40.9K – 1512
2024
Q3 		$40.9K Sell
1,992
-365
-15% -$8.42K ﹤0.01% 1321
2024
Q2 		$52.8K Sell
2,357
-1,339
-36% -$31.9K ﹤0.01% 1282
2024
Q1 		$102K Sell
3,696
-259
-7% -$7.19K ﹤0.01% 1217
2023
Q4 		$121K Sell
3,955
-619
-14% -$17.8K ﹤0.01% 1179
2023
Q3 		$145K Sell
4,574
-142
-3% -$5.51K ﹤0.01% 1152
2023
Q2 		$192K Sell
4,716
-2,060
-30% -$83.5K ﹤0.01% 1127
2023
Q1 		$253K Buy
6,776
+153
+2% +$6K 0.01% 1073
2022
Q4 		$231K Buy
6,623
+2,257
+52% +$107K ﹤0.01% 1107
2022
Q3 		$244K Sell
4,366
-311
-7% -$19.3K 0.01% 1100
2022
Q2 		$242K Buy
4,677
+930
+25% +$47.2K ﹤0.01% 1126
2022
Q1 		$272K Sell
3,747
-258
-6% -$21.9K ﹤0.01% 1156
2021
Q4 		$474K Buy
4,005
+565
+16% +$70.8K 0.01% 1019
2021
Q3 		$461K Buy
3,440
+826
+32% +$125K 0.01% 1034
2021
Q2 		$423K Buy
2,614
+2,462
+1,620% +$192K 0.01% 1061
2021
Q1 		$12K Buy
+152
New +$10.2K ﹤0.01% 1472

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisors Asset Management's NTLA Position: Q4 2024 in Review

Advisors Asset Management sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 1,992 shares — an estimated $40.9K sold.

Advisors Asset Management first reported a position in NTLA in Q1 2021 and held it in 15 quarters. The position peaked at $474K in Q4 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Advisors Asset Management reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Advisors Asset Management sold 1,992 Intellia Therapeutics shares in Q4 2024, an estimated $40.9K.
  • Advisors Asset Management first reported a position in Intellia Therapeutics in Q1 2021 and held it in 15 quarters.
  • Advisors Asset Management's Intellia Therapeutics position peaked at $474K in Q4 2021.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Advisors Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.